Autotaxin-IN-8
Autotaxin-IN-8 (Compound 14E) is an orally active Autotaxin inhibitor with an IC50 of 14.2 nM against hAutotaxin. Autotaxin-IN-8 inhibits Autotaxin activity, MAPK activation, LPAR1 and p-ERK1/2. Autotaxin-IN-8 reduces the phosphorylation levels of JNK and p38. Autotaxin-IN-8 decreases collagen deposition in a mouse model of pulmonary fibrosis. Autotaxin-IN-8 can be used in research related to pulmonary fibrosis.
For research use only. We do not sell to patients.
- CAS No.: 3058084-21-9
- Formula: C21H20ClN9O
- Molecular Weight:449.90
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
ERK1 |
ERK2 |
LPA1 Receptor |
Autotaxin 14.2 nM (IC50) |
In Vitro
Autotaxin-IN-8 (14.2 nM; 2 h) potently inhibits recombinant human ATX enzymatic activity with an in vitro IC50 of 14.2 nM[1].
Autotaxin-IN-8 (94.31 μM; 24 h) shows low cytotoxicity toward human normal lung epithelial L132 cells with an IC50 of 94.31 μM[1].
Autotaxin-IN-8 (1 μM; 12 h) significantly inhibits basal, TGF-β-stimulated, and LPC-stimulated migration of A549 cells over 12 h[1].
Autotaxin-IN-8 (1 μM; 48 h) significantly reduces spontaneous, TGF-β-triggered, and LPC-triggered collagen gel contraction by MLg cells over 48 h[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Human normal lung epithelial L132 cells
-
Concentration:0.1-5.0 μM (concentration-dependent study); 0.5 μM (time-dependent study); 0.5 μM (LPC/LPA co-treatment pre-incubation); 0.5 μM (TGF-β co-treatment pre-incubation)
-
Incubation Time:75 min (concentration-dependent study); 30-75 min (time-dependent study); 75 min pre-incubation + 15 min LPC/LPA stimulation (co-treatment); 3 h pre-incubation + 3 h TGF-β stimulation (co-treatment)
-
Result:Inhibited phosphorylation of p-JNK with an EC50 of 0.958 μM, p-p38 with an EC50 of 0.785 μM, and p-ERK1/2 with an EC50 of 0.297 μM, with marked inhibition at concentrations as low as 0.5 μM.
Inhibited phosphorylation of p-JNK with an estimated time of 35.4 min, p-p38 with an estimated time of 39.13 min, and p-ERK1/2 with an estimated time of 30.46 min, with effects observed within 30 min.
Suppressed LPC-induced activation of p-JNK, p-p38, and p-ERK1/2 but had no effect on LPA-induced activation.
Significantly reduced TGF-β-induced phosphorylation of JNK, ERK, and p38.
Parmacokinetics
| Species | Dose | Route | Tmax | Cmax | T1/2 | AUC0-last |
|---|---|---|---|---|---|---|
| Rat[1] | 1 mg/kg | p.o. | 2.67 h | 135.26 ng/mL | 5.49 h | 631.01 |
In Vivo
Autotaxin-IN-8 (1-3 mg/kg; p.o.; daily; 21 days) reduces collagen deposition, fibrosis marker expression, and inflammation in a Bleomycin (HY-17565A)-induced pulmonary fibrosis mouse model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, 8 weeks old, bleomycin-induced pulmonary fibrosis)[1]
-
Dosage:1 mg/kg; 3 mg/kg
-
Administration:p.o.; daily; 21 days
-
Result:Markedly reduced bleomycin-induced collagen deposition in lung tissue.
Decreased lung tissue expression of α-SMA and TGF-β.
Suppressed the bleomycin-induced increase in LPAR1 and p-ERK1/2.
Mitigated bleomycin-provoked inflammatory responses by reducing IL-1β and IL-6 expression in lung tissue.
Chemical Information
-
CAS No. 3058084-21-9
-
Molecular Weight 449.90
-
Formula C21H20ClN9O
-
SMILES
ClC1=CC=C(C=C1)CCNC2=NC=C(C3=NN=C(N4C[C@@]5([H])[C@H](C6=CN=NN6)[C@@]5([H])C4)O3)C=N2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Fibrosis/Collagen Morphometry
Fibrosis and collagen morphometry is based on the quantitative visualization of fibrillar collagen deposition in tissue sections using histochemical stains such as Sirius Red (Picrosirius Red) or Masson's trichrome, followed by image-based or polarization-enhanced analysis to estimate collagen proportional area as a surrogate of extracellular matrix accumulation during fibrotic remodeling. Sirius Red combined with polarized light microscopy enhances detection of collagen fibers due to birefringence properties, enabling more specific visualization of collagen type I and III fibrils compared to conventional bright-field histology, while whole-section or region-restricted digital morphometry reduces field-selection bias in fibrosis assessment. Alternative quantitative approaches include second harmonic generation (SHG) and two-photon excited fluorescence microscopy, which enable label-free detection of fibrillar collagen and have been validated against histological staining and biochemica
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Collagen: Sirius Red Staining
Sirius Red or picrosirius red staining is a histochemical method for visualizing collagen-rich extracellular matrix in tissue sections, and collagen fibers are detected as red-stained structures under bright-field microscopy with enhanced birefringence under polarized light. Picrosirius red is useful for assessing total collagen organization, distribution, and fibrosis burden, but polarized color should not be interpreted as a definitive collagen type I versus type III readout because color is affected by fiber orientation, thickness, and packing.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Connective Tissue: Masson's Trichrome/Collagen Trichrome Staining
Masson’s Trichrome (collagen/trichrome staining) is a histological technique that differentially stains tissue compartments using sequential acidic dyes to distinguish collagen from muscle and cytoplasmic components based on dye affinity and tissue permeability differences, enabling visualization of fibrosis and connective tissue architecture in histological sections. The classical formulation typically uses Weigert's iron hematoxylin for nuclear staining, Biebrich scarlet-acid fuchsin for cytoplasm and muscle, and aniline blue (or light green variants) for collagen, producing a characteristic blue/green collagen signal contrasted against red cytoplasm and dark nuclei. The staining principle relies on selective displacement of smaller dye molecules by larger anionic dyes in collagen-rich regions under controlled acidified conditions, which enhances collagen-specific dye retention. This property makes the method widely used for fibrosis assessment in organs such as heart, liver, lung, a
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)